MENLO PARK, Calif.--(BUSINESS WIRE)--Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the appointment of Ron Burch, M.D., Ph.D. to its Scientific Advisory Board. Dr. Burch brings significant experience in the development and commercialization of drug delivery and pain management therapeutics.
“I am excited to welcome Dr. Burch to the Allay team. He is an industry expert and clinician whose background blends biomedical research, product development and commercialization, and he has worked on many of the seminal pain management products that are currently available,” said Adam Gridley, Chief Executive Officer of Allay Therapeutics. “His counsel will be invaluable as we progress our pipeline of potentially transformative ultra-sustained analgesic products.”
Dr. Burch currently serves as Chief Executive Officer of Sanguistat, a company developing products to treat bleeding disorders. He previously served as Chief Medical Officer at Naurex, a clinical-stage biopharmaceutical company developing novel NMDA receptor modulators, and Pacira, an industry leader in non-opioid solutions for pain. Dr. Burch has served as Chairman of Zeneca Pharmaceuticals' Global CNS Therapeutics Area Team; co-founder and CEO of AlgoRx Pharmaceuticals, a company that successfully developed a number of therapeutic agents for pain management; CEO and Chairman of Biowave Corporation, a medical device company that successfully launched three neurostimulation products to treat chronic, intractable pain and postoperative pain; and Scientific Advisor of Collegium Pharmaceuticals. He also held various managerial positions with Purdue Pharma, including Vice President of Scientific Evaluations and Immunotherapeutics, Medical Director and Project Manager and Medical Safety Officer for several pain development programs. Dr. Burch was a researcher at the National Institutes of Health, performing research involving neuroreceptor regulation with Nobel Laureate Dr. Julius Axelrod. Dr. Burch obtained a Ph.D. in Pharmacology and M.D. from the Medical University of South Carolina. He holds B.S. degrees in chemistry and marine biology from the College of Charleston.
“Allay is engaging in innovative work to bring about a dramatic transformation in how we guide patients through post-surgical pain management,” said Dr. Burch. “The company’s proprietary technology platform holds tremendous potential to develop a suite of products offering a non-opioid solution to some of the most difficult post-surgical recoveries.”
Allay’s advisory boards also include David Dalury, M.D., an orthopedic surgeon and educator specializing in knee and hip replacement, leading the Company’s Clinical Advisory Board; and scientific advisors Joachim Kohn, Ph.D., a researcher focused on the development of new biomaterials; and Arthur Tipton; Ph.D., a biopharma veteran with extensive drug development experience.
About Allay Therapeutics
Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. Our proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates to deliver pain relief within a targeted site over weeks: an order of magnitude greater than the longest-lasting pain treatments currently available. Our platform and vision were shaped by The Foundry incubator and Lightstone Venture’s Singapore Fund. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore. Learn more at allaytx.com.
